Literature DB >> 18362395

Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000.

Lixin Hao1, Satoshi Toyokawa, Yasuki Kobayashi.   

Abstract

This study estimates the risk of vaccine-associated paralytic poliomyelitis (VAPP) in Japan between 1971 and 2000. We acquired data regarding the number of VAPP cases from the website of the Ministry of Health, Labour and Welfare, and we estimated the number of oral poliovirus vaccines (OPV) administered based on the reported immunization data. Risk was calculated as the ratio between the number of VAPP cases and the number of OPV doses administered. Both the Runs test and the Poisson model were used to analyze the occurrence of VAPP. Thirty-three cases of VAPP were recorded in Japan between 1971 and 2000; approximately one case occurred per year. There were no statistical changes in temporal trends as regards the occurrence of VAPP between 1971 and 2000. The overall risk for VAPP, including both recipient and contact VAPP, was one case per 2.0 million OPV doses administered. The risk of recipient VAPP was one per 3.7 million doses, among which the first dose posed a much higher risk of one per 2.3 million than that of the subsequent dose. These data indicated that the occurrence of VAPP is rare, but the risk has remained constant for as long as OPV has been used in Japan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362395

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  3 in total

1.  Successful Vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Curr Top Microbiol Immunol       Date:  2018-07-26       Impact factor: 4.291

Review 2.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

Review 3.  Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Expert Rev Vaccines       Date:  2020-08-01       Impact factor: 5.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.